ProShares UltraShort NASDAQ Biotechnology
8 hedge funds and large institutions have $984K invested in ProShares UltraShort NASDAQ Biotechnology in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and closing their positions.
14% more funds holding
Funds holding: 7 → 8 (+1)
1.75% more ownership
Funds ownership: 7.7% → 9.45% (+1.8%)
5% more capital invested
Capital invested by funds: $938K → $984K (+$46.5K)
20% less call options, than puts
Call options by funds: $8K | Put options by funds: $10K
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$132K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$6.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$50.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$44.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$21.9K |
| 4 |
Morgan Stanley
New York
|
-$595 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $424K | -$44.8K | -1,130 | -10% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $354K | -$21.9K | -552 | -6% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $173K | +$132K | +3,324 | +407% |
|
|
4
UBS Group
Zurich,
Switzerland
| $22.7K | -$50.3K | -1,267 | -70% |
|
|
5
Simplex Trading
Chicago,
Illinois
| $6K | +$6.51K | +164 | New |
|
|
6
Morgan Stanley
New York
| $2.52K | -$595 | -15 | -20% |
|
7
Citigroup
New York
| $1.77K | – | – | – |
|
8
Osaic Holdings
Scottsdale,
Arizona
| $1.04K | – | – | – |
|
BIS Hedge Fund Activity: Q2 2023 in Review
8 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2023, worth a combined $984K — up 5% from $938K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BIS positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $132K. The largest seller was UBS Group, cutting an estimated $50.3K.
- 8 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2023, up from 7 in Q1 2023.
- Funds reported $984K of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2023, up 5% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2023 and 0 closed out, a net change of +1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2023 was Tower Research Capital (TRC), an estimated $132K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2023 was UBS Group, an estimated $50.3K sold.
Based on aggregated 13F filings for Q2 2023.